Literature DB >> 18217618

Nuclear localization of HIV-1 tat functionalized gold nanoparticles.

C C Berry1, J M de la Fuente, M Mullin, S Wai Ling Chu, A S G Curtis.   

Abstract

The impermeable nature of the cell plasma membrane limits the therapeutic uses of many macromolecules and there is therefore a growing effort to circumvent this problem by designing strategies for targeted intracellular delivery. During the last decade several cell penetrating peptides, such as the HIV-1 tat peptide, have been shown to traverse the cell membrane, where integral protein transduction domains (PTDs) are responsible for their cellular uptake, and to reach the nucleus while retaining biological activity. It has since been discovered that PTDs can enable the cellular delivery of conjugated biomolecules and even nanoparticles, but nuclear delivery has remained problematic. This present study focuses on the development of water soluble, biocompatible gold nanoparticles of differing size functionalized with the HIV-1 tat PTD with the aim of producing nuclear targeting agents. The particles were subsequently tested in vitro with a human fibroblast cell line, with results demonstrating successful nanoparticle transfer across the plasma membrane, with 5 nm particles achieving nuclear entry while larger 30 nm particles are retained in the cytoplasm, suggesting entry is blocked via nuclear pores dimensions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18217618     DOI: 10.1109/tnb.2007.908973

Source DB:  PubMed          Journal:  IEEE Trans Nanobioscience        ISSN: 1536-1241            Impact factor:   2.935


  23 in total

1.  Interaction of α-synuclein and a cell penetrating fusion peptide with higher eukaryotic cell membranes assessed by ¹⁹F NMR.

Authors:  Imola G Zigoneanu; Gary J Pielak
Journal:  Mol Pharm       Date:  2012-03-13       Impact factor: 4.939

Review 2.  A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection.

Authors:  Stephanie D Kraft-Terry; Shilpa J Buch; Howard S Fox; Howard E Gendelman
Journal:  Neuron       Date:  2009-10-15       Impact factor: 17.173

Review 3.  Radiosensitization by gold nanoparticles.

Authors:  B Jeremic; A R Aguerri; N Filipovic
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

4.  TAT peptide-functionalized gold nanostars: enhanced intracellular delivery and efficient NIR photothermal therapy using ultralow irradiance.

Authors:  Hsiangkuo Yuan; Andrew M Fales; Tuan Vo-Dinh
Journal:  J Am Chem Soc       Date:  2012-07-09       Impact factor: 15.419

Review 5.  Neuroimmune pharmacology of neurodegenerative and mental diseases.

Authors:  Feng-Shiun Shie; Yun-Hsiang Chen; Chia-Hsiang Chen; Ing-Kang Ho
Journal:  J Neuroimmune Pharmacol       Date:  2010-09-07       Impact factor: 4.147

Review 6.  Targeted hyperthermia using metal nanoparticles.

Authors:  Paul Cherukuri; Evan S Glazer; Steven A Curley
Journal:  Adv Drug Deliv Rev       Date:  2009-11-10       Impact factor: 15.470

7.  Effects of TAT-conjugated platinum nanoparticles on lifespan of mitochondrial electron transport complex I-deficient Caenorhabditis elegans, nuo-1.

Authors:  Yuri Sakaue; Juewon Kim; Yusei Miyamoto
Journal:  Int J Nanomedicine       Date:  2010-09-20

8.  The potential of nanomedicine therapies to treat neovascular disease in the retina.

Authors:  Krysten M Farjo; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-10-08

9.  The in vitro sub-cellular localization and in vivo efficacy of novel chitosan/GMO nanostructures containing paclitaxel.

Authors:  W J Trickler; A A Nagvekar; A K Dash
Journal:  Pharm Res       Date:  2009-05-20       Impact factor: 4.200

10.  Tracking mesenchymal stromal cells using an ultra-bright TAT-functionalized plasmonic-active nanoplatform.

Authors:  Hsiangkuo Yuan; Jose A Gomez; Jennifer S Chien; Lunan Zhang; Christy M Wilson; Shuqin Li; Andrew M Fales; Yang Liu; Gerald A Grant; Maria Mirotsou; Victor J Dzau; Tuan Vo-Dinh
Journal:  J Biophotonics       Date:  2015-09-11       Impact factor: 3.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.